Investigation announced for Investors in Revvity, Inc. (NYSE: RVTY) over possible Violations of Securities Laws

An investigation on behalf of investors of Revvity, Inc. (NYSE: RVTY) shares over potential securities laws violations by Revvity, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Revvity, Inc. (NYSE: RVTY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Revvity, Inc. (NYSE: RVTY) concerning whether a series of statements by Revvity, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Waltham, MA based Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics.

Revvity, Inc. reported that its annual Total Revenue declined from over $5.06 billion in 2021 to over $3.31 billion in 2022, and that its Net Income decreased from $932.15 million in 2021 to $579.17 million in 2022.

On October 30, 2023, Revvity, Inc. reported disappointing results for its third quarter of 2023, including non-GAAP earnings-per-share of $1.18, missing consensus estimates by $0.01, and revenue of $670.74 million, missing consensus estimates by $23.78 million and representing a 5.8% year-over-year decline. The Company also slashed its full year 2023 revenue guidance to between $2.72 billion and $2.74 billion, compared to its prior revenue forecast of $2.8 billion to $2.85 billion, as well as analysts' estimates of $2.83 billion. On a conference call to discuss Revvity's results, the Company's Chief Financial Officer noted that there was a "noticeable step down" in demand from Revvity's pharmaceutical and biotech clients, particularly in September. In addition, Revvity advised that weakness in demand for its diagnostics and contract research solutions would likely continue at least into the first half of the next year.

Shares of Revvity, Inc. (NYSE: RVTY) declined to as low as $79.50 per share on October 30, 2023.

Those who purchased shares of Revvity, Inc. (NYSE: RVTY) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.